Publications by authors named "Marta Garcia-Culebras"
Article Synopsis
- - The addition of molecular data to prognostic models has improved the risk assessment of low-risk myelodysplastic neoplasms (LR-MDS), but the specific impact of molecular lesions in this group remains uncertain.
- - In a study of 227 LR-MDS patients, RUNX1 mutations were linked to lower overall survival, while SF3B1 mutations showed a reduced risk of death; both TP53 and RUNX1 mutations were also predictive of leukaemic progression.
- - The traditional measure of blast percentage did not significantly affect survival or progression probabilities in LR-MDS patients when molecular data was included, highlighting its decreased clinical relevance in this context.
Introduction: Prognosis of patients with myelodysplastic syndrome (MDS), particularly the group with lower-risk disease (LR-MDS) is very heterogeneous. Several studies have described the prognostic value of recurrent somatic mutations in MDS including all risk categories. Recently, the incorporation of genomic data to clinical parameters defined the new Molecular International Prognostic Scoring System (IPSS-M).
View Article and Find Full Text PDF